Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Researchers develop novel oxygen-independent therapy for cancer

Researchers develop novel oxygen-independent therapy for cancer

UCLA develops largest collection of patient-derived organoids for sarcoma research

UCLA develops largest collection of patient-derived organoids for sarcoma research

Bioactive glasses with gallium show promise for bone cancer treatment

Bioactive glasses with gallium show promise for bone cancer treatment

Review explores WNT5B and WNT10B roles in osteosarcoma

Review explores WNT5B and WNT10B roles in osteosarcoma

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma

Study provides novel insights into the molecular mechanisms of melanoma progression

Study provides novel insights into the molecular mechanisms of melanoma progression

Europe's new clinical guidelines enable better understanding of childhood bone cancer

Europe's new clinical guidelines enable better understanding of childhood bone cancer

New type of immunotherapy shows promising preclinical results against osteosarcoma

New type of immunotherapy shows promising preclinical results against osteosarcoma

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

Evaluating ChatGPT for structured data extraction from clinical notes

Evaluating ChatGPT for structured data extraction from clinical notes

New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns

New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns

Expanding research and clinical options for children with cancer

Expanding research and clinical options for children with cancer

Advancing osteosarcoma prognosis with AI-assisted tumor cell density analysis

Advancing osteosarcoma prognosis with AI-assisted tumor cell density analysis

Researchers discover new class of compound that targets cancer stem cells

Researchers discover new class of compound that targets cancer stem cells

Study delves into the molecular intricacies of osteosarcoma in elderly patients

Study delves into the molecular intricacies of osteosarcoma in elderly patients

Genetic mutation in OXR1 gene linked to brain development issues

Genetic mutation in OXR1 gene linked to brain development issues

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

AI model calculates percent necrosis in osteosarcoma patients with 99% accuracy

AI model calculates percent necrosis in osteosarcoma patients with 99% accuracy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.